Lonza Tampa to Import Psychedelic Shrooms for Science
Published Date: 2/18/2025
Notice
Summary
Lonza Tampa, LLC wants to become an official importer of psilocybin, a controlled substance. This means they’ll be allowed to bring this drug into the U.S. for research or medical use. People who make or use these drugs can share their thoughts or ask for a hearing by March 20, 2025.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Approval Would Allow Psilocybin Imports for Research
Lonza Tampa, LLC applied on February 4, 2025 to be registered to import psilocybin (drug code 7437, Schedule I) as bulk active pharmaceutical ingredient and as finished dosage units for clinical trials, research, and analytical purposes. If approved, that registration would authorize Lonza Tampa to import those kinds of psilocybin shipments for research use. Stakeholders may submit comments or request a hearing by March 20, 2025.
Commercial Import of Finished Psilocybin Not Authorized
The notice states that authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms of psilocybin for commercial sale. That means this registration, if issued, would not permit importing finished psilocybin products for commercial retail or distribution.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.
Previous / Next Documents
Previous: 2025-02733, Bulk Manufacturer of Controlled Substances Application: Scottsdale Research Institute
Scottsdale Research Institute wants to become a big-time maker of marijuana and related substances for research and clinical trials. If you’re a current manufacturer or interested party, you can share your thoughts or ask for a hearing by April 21, 2025. This move helps boost scientific studies but doesn’t change any other drug activities or costs right now.
Next: 2025-02738, Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to become a big-time maker of special research drugs called psilocybin and psilocyn. They plan to import these substances to help with science and medicine, not to sell or distribute them. If you have thoughts or want a hearing, you’ve got until April 21, 2025, to speak up!